Most patients ask me for a coronary calcium score because they want a number that gives them permission to do nothing. A zero feels like a clean bill of health — proof the arteries are quiet, the future is far away, and the statin conversation can wait.

I understand the appeal. I also think it is one of the most consequential misreadings in preventive cardiology. A study published this month gave me the cleanest illustration of why I have seen in years.

NATURE-CT, in the Journal of Cardiovascular Computed Tomography, is unusual because of what it deliberately left out. The investigators identified 205 adults from two Los Angeles imaging centers who each had two clinically indicated coronary CT angiograms at least two years apart, a baseline calcium score of 100 or less, and no heart attack or revascularization in between. The defining feature: no lipid-lowering therapy of any kind between scans — no statin, no ezetimibe, no PCSK9 inhibitor, nothing. They excluded diabetes, familial hypercholesterolemia, and chronic kidney disease.

What that design produces is something we almost never get to see ethically: untreated atherosclerosis, measured serially, in people who look low-risk on paper. A natural-history cohort. The closest thing to the control arm we are not allowed to randomize.

And the population was reassuring by every conventional metric. Mean age 55. Mean baseline LDL of 112 mg/dL — a number most clinicians would not blink at. Over half had a calcium score of zero. These are exactly the patients who walk out of the office relieved.

Over a median of roughly five years, total plaque volume essentially doubled — from a median of about 30 mm³ to 59 mm³, an annualized increase near 6.7 mm³ per year. The growth was overwhelmingly non-calcified: soft plaque climbed about 4.9 mm³ per year while calcified plaque crept up just 0.4. And low-attenuation plaque — the lipid-rich, inflamed tissue most tightly linked to events — was present in 9% at baseline and 23% at follow-up.

To put that rate in context: in statin-treated cohorts imaged the same way, total plaque tends to climb far more slowly, and the dangerous non-calcified fraction often stalls or shrinks even as calcium rises. Here, untreated, both kept climbing. That is the comparison worth holding in mind — not whether 59 mm³ is a frightening number in isolation, but the direction and pace of travel when nothing is done.

This was not a story of a few outliers dragging the average. Most of the cohort progressed gradually rather than explosively — only about 3% qualified as rapid progressors by the usual percent-atheroma-volume threshold, and roughly 11% crossed an intermediate one. The point is the baseline: in an untreated, low-risk group, the default direction of travel was forward, not flat.

Read that last line again. Among the subjects who were rescanned with a calcium image, the share with a score of zero fell from 41% to 31%. The zeros were converting. The reassurance had an expiration date.